FDA: Silicone Breast Implants Are Safe, But Safety Studies Must Continue

Follow us

The FDA approved silicone gel-filled breast implants, made and sold by Allergan and Johnson & Johnson's Mentor in 2006, on condition both companies follow 40,000 women for 10 years to look at safety issues, as well as extend smaller pre-approval studies.

"It's unacceptable that many patients Mentor and Allergan were supposed to track were lost," said Jan Erickson, of the National Organization for Women Foundation.

Allergan has collected preliminary two-year data for 60 percent of participants, while Mentor has collected three-year data for only 21 percent.

"Mentor's approval should be rescinded right away. And Allergan should be required to conduct further studies," the group said.

There were almost 400,000 breast enlargement or reconstruction procedures in the United States in 2010, according to the American Society of Plastic Surgeons, which includes silicone and saline implants.

In June, the FDA said the risks of breast implants are well understood, after looking at the companies' results as well as reports of negative events and scientific literature, it said women who get silicone implants are likely to need additional surgery within ten years.

The agency had banned silicone implants for most U.S. women in 1992 after some said the devices leaked and made them chronically ill.

During the Tuesday meeting, patients complained of side effects such as rupturing or hardening of the device, and said the companies' long-term studies could be biased against patients who have problems.

Mentor also said it may have had particularly low response rates because the company made patients participate in the study as a condition of getting an implant, but later changed it to voluntary participation.

"In retrospect, it's perhaps not surprising that if a patient or surgeon enrolls because they are required to, and then a patient is told because of voluntary consent they're not ... that might contribute to low follow-up rates," said Dr. John Canady, medical director at Mentor, when asked if the company's study had any design flaws.

"That's something we would go back to change, but obviously can't in this study," Canady said.

Jean Silver-Isenstadt, executive director of the National Physicians Alliance, said the FDA needed to show its commitment to enforcing post-approval studies.

"We believe that this agency has to walk the walk," Silver-Isenstadt told Reuters. "Its mission is to protect patients, and when it sets criteria for approval, that should be real.

The advisory panel will make its final recommendations on post-approval studies on Wednesday.